Rapid Micro Biosystems Inc RPID.OQ RPID.O is expected to show a rise in quarterly revenue when it reports results on August 12 for the period ending June 30 2025
The Lexington Massachusetts-based company is expected to report a 6.3% increase in revenue to $7.033 million from $6.62 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Rapid Micro Biosystems Inc is for a loss of 25 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Rapid Micro Biosystems Inc is $8.00, about 58.1% above its last closing price of $3.35
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.27
-0.27
-0.26
Beat
3.7
Dec. 31 2025
-0.23
-0.23
-0.22
Beat
4.3
Sep. 30 2024
-0.25
-0.26
Missed
-2
Jun. 30 2024
-0.28
-0.28
-0.29
Missed
-4.8
Mar. 31 2024
-0.29
-0.29
-0.31
Missed
-6.9
Dec. 31 2023
-0.30
-0.30
-0.26
Beat
13.3
Sep. 30 2023
-0.30
-0.31
-0.31
Met
-1.1
Jun. 30 2023
-0.35
-0.35
-0.33
Beat
5.7
This summary was machine generated August 8 at 17:41 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)